Akari Therapeutics (AKTX) Competitors $1.18 -0.29 (-19.73%) (As of 10:31 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends AKTX vs. COCP, MURA, VHAQ, ENTX, AADI, THTX, KZR, UNCY, VOR, and KRONShould you be buying Akari Therapeutics stock or one of its competitors? The main competitors of Akari Therapeutics include Cocrystal Pharma (COCP), Mural Oncology (MURA), Viveon Health Acquisition (VHAQ), Entera Bio (ENTX), Aadi Bioscience (AADI), Theratechnologies (THTX), Kezar Life Sciences (KZR), Unicycive Therapeutics (UNCY), Vor Biopharma (VOR), and Kronos Bio (KRON). These companies are all part of the "pharmaceutical products" industry. Akari Therapeutics vs. Cocrystal Pharma Mural Oncology Viveon Health Acquisition Entera Bio Aadi Bioscience Theratechnologies Kezar Life Sciences Unicycive Therapeutics Vor Biopharma Kronos Bio Akari Therapeutics (NASDAQ:AKTX) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, community ranking, media sentiment, institutional ownership and profitability. Which has more volatility and risk, AKTX or COCP? Akari Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Cocrystal Pharma has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500. Is AKTX or COCP more profitable? Akari Therapeutics' return on equity of 0.00% beat Cocrystal Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Akari TherapeuticsN/A N/A N/A Cocrystal Pharma N/A -94.62%-78.24% Does the media refer more to AKTX or COCP? In the previous week, Akari Therapeutics had 5 more articles in the media than Cocrystal Pharma. MarketBeat recorded 9 mentions for Akari Therapeutics and 4 mentions for Cocrystal Pharma. Cocrystal Pharma's average media sentiment score of 0.76 beat Akari Therapeutics' score of 0.19 indicating that Cocrystal Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akari Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cocrystal Pharma 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in AKTX or COCP? Akari Therapeutics received 239 more outperform votes than Cocrystal Pharma when rated by MarketBeat users. However, 76.67% of users gave Cocrystal Pharma an outperform vote while only 52.09% of users gave Akari Therapeutics an outperform vote. CompanyUnderperformOutperformAkari TherapeuticsOutperform Votes26252.09% Underperform Votes24147.91% Cocrystal PharmaOutperform Votes2376.67% Underperform Votes723.33% Which has better earnings and valuation, AKTX or COCP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkari TherapeuticsN/AN/A-$10.01MN/AN/ACocrystal PharmaN/AN/A-$17.98M-$1.85-1.19 Do analysts rate AKTX or COCP? Cocrystal Pharma has a consensus target price of $7.00, suggesting a potential upside of 218.18%. Given Cocrystal Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Cocrystal Pharma is more favorable than Akari Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akari Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cocrystal Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders hold more shares of AKTX or COCP? 5.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are owned by institutional investors. 38.9% of Akari Therapeutics shares are owned by company insiders. Comparatively, 25.6% of Cocrystal Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryCocrystal Pharma beats Akari Therapeutics on 7 of the 13 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Get Akari Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKTX vs. The Competition Export to ExcelMetricAkari TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.34M$6.48B$5.07B$8.80BDividend YieldN/A8.11%4.99%4.07%P/E RatioN/A4.9789.5613.60Price / SalesN/A371.451,224.8087.40Price / CashN/A52.5939.4536.27Price / Book-39.3310.306.976.33Net Income-$10.01M$153.61M$119.04M$225.93M7 Day Performance-47.09%-1.73%-1.78%-0.96%1 Month Performance-45.37%-7.26%-3.59%1.06%1 Year Performance-61.31%31.10%31.64%26.59% Akari Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKTXAkari TherapeuticsN/A$1.18-19.7%N/A-55.0%$14.34MN/A0.009Analyst ForecastNews CoverageHigh Trading VolumeCOCPCocrystal Pharma3.0393 of 5 stars$2.20+6.8%$7.00+218.2%+25.6%$22.37MN/A-1.1910Gap UpMURAMural Oncology3.191 of 5 stars$3.36-0.3%$16.00+376.2%N/A$57.19MN/A0.00119Analyst RevisionPositive NewsVHAQViveon Health AcquisitionN/A$10.00flatN/AN/A$56.60MN/A0.002High Trading VolumeENTXEntera Bio2.0488 of 5 stars$1.56+0.6%$10.00+541.0%+112.3%$55.82M$130,000.000.0020Gap UpAADIAadi Bioscience1.1874 of 5 stars$2.26+1.8%$1.67-26.3%-53.3%$55.71M$24.35M0.0040THTXTheratechnologiesN/A$1.21-0.8%N/A-10.3%$55.64M$81.76M-12.20140Positive NewsKZRKezar Life Sciences4.3605 of 5 stars$7.55+0.8%$40.50+436.4%-15.4%$55.12M$7M0.0060Analyst RevisionUNCYUnicycive Therapeutics3.4448 of 5 stars$0.52+1.8%$5.13+887.9%-2.0%$53.85M$680,000.000.009Analyst RevisionGap UpVORVor Biopharma1.7132 of 5 stars$0.78-1.5%$11.36+1,350.5%-53.0%$53.77MN/A0.00140KRONKronos Bio3.1795 of 5 stars$0.89+3.6%$1.63+82.4%-28.3%$53.76M$6.29M0.00100 Related Companies and Tools Related Companies Cocrystal Pharma Competitors Mural Oncology Competitors Viveon Health Acquisition Competitors Entera Bio Competitors Aadi Bioscience Competitors Theratechnologies Competitors Kezar Life Sciences Competitors Unicycive Therapeutics Competitors Vor Biopharma Competitors Kronos Bio Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AKTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akari Therapeutics, Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Akari Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AKTX Stock Alerts